PRNewswire · Sep 2025
LEAH Labs and the University of Missouri reported world-first remission in two canine B-cell lymphoma patients treated with CAR-T cells isolated using Akadeum's kit.
Living therapies for pets first, and their people next
Company research
Public company, workplace, funding, and market signals
Overview
LEAH Labs is a translational veterinary biotechnology company building designer cell therapies for dogs, starting with CAR-T for B-cell lymphoma, and using its virus-free GeneWeld gene-editing platform and One Health approach to inform human cancer therapies.
Primary product
CAR-T cell therapy for dogs with B-cell lymphoma
Founded
2018
Headquarters
Eagan, Minnesota, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Cell therapy / veterinary oncology
Offices
Eagan, Minnesota, United States
Rochester, Minnesota, United States
Minneapolis, Minnesota, United States
Business model
clinical-stage translational biotech
veterinarian-mediated therapeutic channel
grant-funded R&D
Funding
Stage
seed / grant-funded pre-clinical
Total raised
$5.8M
Latest round
NCI SBIR-TT Phase I grant · Sep 2025
Latest amount
$400K
People & investors
Leadership
Founder & CEO
Chief Scientific Officer
Scientific Founder & Board Director
Scientific Founder
Co-Founder
Work & culture
Mission-driven, founder-led, lean-startup culture with a fast-paced research environment focused on translational science and One Health.
Compensation
Public hiring evidence points to competitive salary commensurate with experience and credentials, plus equity, health care benefits, responsible PTO, and paid holidays.
Benefits
company equity
responsible PTO
paid holidays
health care benefits
Product & market
Pricing
Current treatment is free to enrolled families in trials; long-term target pricing is about $500 per CAR-T dose.
Differentiators
- —virus-free GeneWeld platform
- —first/only reported canine CAR-T remissions
- —USDA-regulated path instead of FDA for pet therapies
- —One Health translational model using naturally occurring canine cancers
- —published PET-imaging-enabled live-cell-therapy trials
- —ability to engineer primary human T cells for veterinary use
Technology
GeneWeld virus-free gene editing
CAR-T cell engineering
Python
C
Cloudflare
Google Global Site Tag
Google Universal Analytics
AI/protein design
3D tumor assays
PET imaging
Customers
pet parents with dogs diagnosed with cancer
licensed veterinarians
veterinary oncology clinics and specialty oncologists
partner academic veterinary hospitals
Scale & contact
Estimated revenue
$0-$1M
Estimated monthly visits
1.1K
Latest news
Medical Alley · Sep 2025
LEAH Labs received a $400,000 NCI SBIR-TT Phase I grant and a non-exclusive NIH patent license to study c-Myb overexpression for reducing CAR-T exhaustion.
Medical Alley · Aug 2025
LEAH Labs won a $500,000 NSF SBIR Phase IIB grant and reported roughly $5.8M in total non-dilutive funding and investments as of August 2025.
Medical Alley · Jun 2025
LEAH Labs received a $50,000 G-Rex grant to improve CAR-T manufacturing throughput and lower costs using GeneWeld plus G-Rex outgrowth.
Newsweek · Jan 2025
Early trials of LEAH Labs and University of Missouri CAR-T therapy for canine lymphoma showed rapid tumor reduction and remission in two dogs, with a focus on translational insights for human lymphoma research.
Jobs and careers at LEAH Labs
0 jobs at LEAH Labs
No open positions
Check back later for new openings